Earnings Summary

Kiniksa Pharmaceuticals Ltd’s revenue jumped 34.76% since last year same period to $83.4Mn in the Q4 2023. On a quarterly growth basis, Kiniksa Pharmaceuticals Ltd has generated 24.38% jump in its revenue since last 3-months.

Kiniksa Pharmaceuticals Ltd’s net profit jumped 465.73% since last year same period to $25.24Mn in the Q4 2023. On a quarterly growth basis, Kiniksa Pharmaceuticals Ltd has generated 282.15% jump in its net profits since last 3-months.

Kiniksa Pharmaceuticals Ltd’s net profit margin jumped 319.8% since last year same period to 30.26% in the Q4 2023. On a quarterly growth basis, Kiniksa Pharmaceuticals Ltd has generated 246.44% jump in its net profit margins since last 3-months.

Kiniksa Pharmaceuticals Ltd’s price-to-earnings ratio after this Q4 2023 earnings stands at 87.2.

Kiniksa Pharmaceuticals Ltd’s earning per share (EPS) estimates for the current quarter stand at -0.16 - a -14.29% fall from last quarter’s estimates.

Kiniksa Pharmaceuticals Ltd’s earning per share (EPS) estimates for the current year stand at -0.16.

Kiniksa Pharmaceuticals Ltd’s earning per share (EPS) jumped 483.33% since last year same period to 0.35 in the Q4 2023. This indicates that the Kiniksa Pharmaceuticals Ltd has generated 483.33% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Kiniksa Pharmaceuticals Ltd’s return on assets (ROA) stands at -0.03.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Kiniksa Pharmaceuticals Ltd’s return on equity (ROE) stands at 0.03.